Institutional shares held 127 Million
1.7K calls
18K puts
Total value of holdings $747M
$10K calls
$106K puts
Market Cap $686M
120,219,000 Shares Out.
Institutional ownership 105.35%
# of Institutions 180


Latest Institutional Activity in RLAY

Top Purchases

Q3 2024
Sg Americas Securities, LLC Shares Held: 55.1K ($315K)
Q3 2024
New York State Common Retirement Fund Shares Held: 84.5K ($482K)
Q3 2024
Raymond James Financial Services Advisors, Inc. Shares Held: 100K ($571K)
Q3 2024
Raymond James & Associates Shares Held: 66.8K ($382K)
Q3 2024
Values First Advisors, Inc. Shares Held: 10.6K ($60.4K)

Top Sells

Q3 2024
Exchange Traded Concepts, LLC Shares Held: 20.6K ($118K)
Q3 2024
Congress Asset Management CO Shares Held: 146K ($836K)
Q3 2024
Us Bancorp \De\ Shares Held: 1.07K ($6.08K)
Q3 2024
Nisa Investment Advisors, LLC Shares Held: 2.34K ($13.4K)
Q3 2024
Allworth Financial LP Shares Held: 318 ($1.82K)

About RLAY

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.


Insider Transactions at RLAY

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.8M Shares
From 7 Insiders
Grant, award, or other acquisition 1.67M shares
Exercise of conversion of derivative security 129K shares
Sell / Disposition
278K Shares
From 5 Insiders
Open market or private sale 278K shares

Track Institutional and Insider Activities on RLAY

Follow Relay Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RLAY shares.

Notify only if

Insider Trading

Get notified when an Relay Therapeutics, Inc. insider buys or sells RLAY shares.

Notify only if

News

Receive news related to Relay Therapeutics, Inc.

Track Activities on RLAY